A pivotal lung cancer hit in an outdated setting means the company might struggle with adoption.
Lung cancer approval for the group’s electric fields-based therapy could come this year, but Novocure has broader solid tumour ambitions.
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.